Anti-Psychotic for Mental Disorder: 39.3% of denials overturned
In 28 California IMR decisions from 2005 to 2025, reviewers overturned 11 (39.3%). In the last five years: 44.4% of 9. 24 were medical-necessity disputes, 4 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 5 | 20.0% |
| 2022 | 1 | 0.0% |
| 2023 | 1 | 100.0% |
| 2024 | 1 | 100.0% |
| 2025 | 1 | 100.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 10 | 40.0% | 39.3% |
| FDA approval or off-label use discussedThe findings discuss the FDA label status of the treatment. | 7 | 28.6% | 39.3% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 5 | 0.0% | 39.3% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Vraylar. Vraylar (cariprazine) is U.S. Food and Drug Administration (FDA)-approved as adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults. Clinical trials demonstrate that cariprazine, as an adjunctive therapy to antidepressants, produces statistically significant improvements in depressive symptoms. …”
“The physician reviewer found that the patient has requested reimbursement for Viibryd (brand). Current medical literature supports the use of Viibryd for the treatment of major depressive disorder and notes that it provides benefits for symptoms of anxiety as well. In this case, the patient has tried numerous antidepressants along with psychotherapy without sufficient effect and with continued significant mood …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Caplyta. The U.S. Food and Drug Administration (FDA) recently endorsed an expanded indication for Caplyta for the treatment of bipolar I and II depressive episodes in adult patients. Caplyta has a unique pharmacodynamic profile characterized by concomitant modulation of dopaminergic, serotonergic, and …”
And one the reviewer upheld
“Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Rexulti 1 mg daily.Findings: The physician reviewer found that records provided for review document that this patient presents with a history of moderate major depressive disorder and generalized anxiety disorder. The records indicate that the patient’s conditions have been non-responsive to multiple therapies including selective serotonin reuptake …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Anti-Psychotic denials for Mental Disorder overturned?
In 28 California IMR decisions from 2005 to 2025, reviewers overturned 11 (39.3%). In the last five years: 44.4% of 9. 24 were medical-necessity disputes, 4 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.